Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Thoracic radiotherapy and concurrent almonertinib for unresectable stage III EGFR-mutated non-small-cell lung cancer: a phase 2 study.

BMC cancer - 7 May 2021

Zhu Lucheng, Zou Changlin, Zhang Zhanchun, Wang Jianfang, Yang Li, Rao Chuangzhou, Yang Zhiping, Liang Jiafeng, Xia Bing, Shenglin M A

Abstract excerpt

BACKGROUND: Concurrent chemo-radiotherapy remains the standard treatment in unresectable stage III non-small-cell lung cancer (NSCLC) patients. Several studies have shown a potential value of concurrent epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) with thoracic radiotherapy in EGFR-mutated population, but a high risk of radiation pneumonitis raised a major concern. This study intends to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acrylamides
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Chemoradiotherapy

Share to ErbB Receptors

Share to Indoles

Share to Neoplasm Staging

Share to Protein Kinase Inhibitors

Share to Pyrimidines

Source

Open in PubMed Open full text

Identifiers

PMID: 33962566
DOI: 10.1186/s12885-021-08266-w
PMCID: PMC8103745

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Thoracic radiotherapy and concurrent almonertinib for unresectable stage III EGFR-mutated non-small-cell lung cancer: a phase 2 study.PMID 33962566Read ↗

Radiotherapy combined with EGFR-TKIs for stage III EGFR-Mutated lung cancer: A retrospective cohort studySemantic proximity Read ↗

Thoracic radiotherapy synergizes with first-line EGFR-TKIs in advanced EGFR-mutant NSCLC: A dual-center real-world study.Semantic proximity Read ↗

EGFR-mutated stage IV non-small cell lung cancer: What is the role of radiotherapy combined with TKI?Semantic proximity Read ↗

Efficacy and safety of EGFR inhibitors and radiotherapy in locally advanced non-small-cell lung cancer: a meta-analysis.Semantic proximity Read ↗

Thoracic Radiotherapy and Radiation Time Would Affect the Efficacy of Advanced Non-Small Cell Lung Cancer for Patients Who Responded to TKIs Treatment.Semantic proximity Read ↗

Comparison of the Incidence Rate of Radiation Pneumonitis Observed in Patients with Advanced Lung Adenocarcinoma Treated with Simultaneous Thoracic Radiotherapy and 1G/2G/3G EGFR-TKIsSemantic proximity Read ↗

Third-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Plus Thoracic Radiotherapy Improves Survival in Patients with Epidermal Growth Factor Receptor-Mutated Stage IV Non-Small Cell Lung CancerSemantic proximity Read ↗

Thoracic Radiotherapy Improves the Survival in Patients With EGFR-Mutated Oligo-Organ Metastatic Non-Small Cell Lung Cancer Treated With Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors: A Multicenter, Randomized, Controlled, Phase III Trial.Semantic proximity Read ↗

Evaluating the Efficacy of EGFR-TKIs Combined With Radiotherapy in Advanced Lung Adenocarcinoma Patients With EGFR Mutation: A Retrospective Study.Semantic proximity Read ↗

Overlap time is an independent risk factor of radiation pneumonitis for patients treated with simultaneous EGFR-TKI and thoracic radiotherapySemantic proximity Read ↗

Erlotinib Versus Etoposide/Cisplatin With Radiation Therapy in Unresectable Stage III Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer: A Multicenter, Randomized, Open-Label, Phase 2 Trial.Semantic proximity Read ↗

Safety and efficacy of consolidative stereotactic radiotherapy for oligo-residual EGFR-mutant non-small cell lung cancer after first-line third-generation EGFR-tyrosine kinase inhibitors: a single-arm, phase 2 trialSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.